Bipolar Soft Tissue Ablation System

The system also features a low profile jaw for easier placement and maneuverability around surrounding structures. Pre-clinical studies have demonstrated that the ablation lines are consistently transmural in thicker tissues. The Isolator Synergy is a product of AtriCure (Cincinnati, OH, USA) and has been approved by the U.S. Food and Drug Administration (FDA) for the ablation of soft tissue. The device is not yet cleared for the ablation of cardiac tissue.

"My initial experience with the Isolator Synergy was that the ablation line was visible and appeared robust. We successfully tested the ablation line for conduction block. I look forward to the further evaluation of this technology, said Patrick M. McCarthy, M.D., chief of the division of cardiothoracic surgery at Northwestern Memorial Hospital (Chicago, IL, USA).

"It has been well established that electrical impulses can propagate across narrow lesions, even if full thickness is achieved due to the reconnection of tissue across the ablation line. We believe that the ablation column created by the Isolator Synergy System will produce superior technical endpoints resulting in improved long-term outcomes,” said David J. Drachman, president and CEO of AtriCure.


Related Links:
AtriCure